Industry Roundup
This article was originally published in The Tan Sheet
Executive Summary
FDA warns eye supplement marketer; Kentucky age-restricts OTC DXM sales; FDA, EPA data-sharing pact; Colorado, Maine pass microbead laws; and more news in brief.
You may also be interested in...
Trade Groups Expand Caffeine Labeling To Stave Off Tighter Regs
The Council for Responsible Nutrition and the American Herbal Products Association amend guidelines and requirements for labeling and marketing caffeine-containing products, going beyond the law in response to congressional and public health complaints about the ingredient’s safety.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.